13F reference period
Q2 2026
Security Snapshot
Xilio Therapeutics, Inc. - Common stock, par value $0.0001 per share (XLO) Institutional Ownership
CUSIP: 98422T209
13F Institutional Holders and Ownership History from Q1 2026 to Q2 2026
Institutions Reporting
26
Shares (Excl. Options)
2.76M
Full value: 2,756,913 · shares · 30 Jun 2026Price
$9.58
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common stock, par value $0.0001 per share
- Symbol
- XLO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 2,756,913
- Total 13F value
- $26,411,048
- Portfolio coverage rank
- 0%
- Share change
- +792,027
- Value change
- +$7,834,041
- Number of holders
- 26
- Shares outstanding
- 6,619,642
- SEC-reported price per share
- $9.15
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- XLO - Xilio Therapeutics, Inc. - Common stock, par value $0.0001 per share is tracked under CUSIP 98422T209.
- 26 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 23 to 26 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$16.56M
Full value: $16,560,762 · USD · 31 Mar 2026.$26.41M
Full value: $26,411,048 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 26 institutions filings for Q2 2026.
Security key
98422T209
13F reference period
Q2 2026
13F holders
26
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
XLO full holder history
Xilio Therapeutics, Inc. SEC filings
Xilio Therapeutics, Inc. company facts
Xilio Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98422T209:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
XLO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| STEMPOINT CAPITAL LP | 9.5% | $5,810,722 | 628,866 | StemPoint Capital LP | 30 Jun 2026 |
As of 30 Jun 2026,
26
institutional investors reported holding
shares of
Xilio Therapeutics, Inc. - Common stock, par value $0.0001 per share (XLO).
This represents
42%
of the company’s total
outstanding shares.
2.76M
Full value: 2,756,913 · shares · 30 Jun 20266.62M
Full value: 6,619,642 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
42%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 10% | 664,021 | 0% | 0.38% | $6,361,322 |
| ORBIMED ADVISORS LLC | 8.9% | 592,300 | 0.11% | $5,674,234 | |
| Frazier Life Sciences Management, L.P. | 6.4% | 422,505 | 0% | 0.09% | $4,047,598 |
| Stonepine Capital Management, LLC | 3.4% | 225,994 | +252% | 1.7% | $2,165,023 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.7% | 178,517 | +44% | 0% | $1,710,193 |
| Sio Capital Management, LLC | 2.3% | 152,464 | 0% | 0.25% | $1,460,605 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.7% | 111,541 | 0% | $1,068,563 | |
| Merck & Co., Inc. | 1.6% | 105,982 | 0% | 0.19% | $1,015,308 |
| RENAISSANCE TECHNOLOGIES LLC | 0.97% | 64,153 | +29% | 0% | $614,586 |
| MORGAN STANLEY | 0.86% | 56,954 | -0.94% | 0% | $545,619 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.59% | 39,055 | +5% | 0% | $374,174 |
| CITADEL ADVISORS LLC | 0.39% | 25,950 | 0% | $248,601 | |
| VANGUARD FIDUCIARY TRUST CO | 0.34% | 22,594 | -21% | 0% | $216,451 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.27% | 17,544 | 0% | $168,072 | |
| TWO SIGMA INVESTMENTS, LP | 0.22% | 14,544 | 0% | $139,332 | |
| Velan Capital Investment Management LP | 0.22% | 14,285 | 0% | 0.08% | $136,850 |
| GSA CAPITAL PARTNERS LLP | 0.21% | 13,590 | -20% | 0.01% | $130,000 |
| STATE STREET CORP | 0.2% | 13,311 | 0% | 0% | $127,519 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.18% | 11,600 | 0.01% | $111,128 | |
| BlackRock, Inc. | 0.13% | 8,757 | 0% | $83,892 | |
| Steward Partners Investment Advisory, LLC | 0.01% | 714 | 0% | $6,840 | |
| SECURITY NATIONAL BANK OF SIOUX CITY IOWA /IA/ | 0% | 321 | 0% | $3,075 | |
| BARCLAYS PLC | 0% | 115 | 0% | $1,102 | |
| Key Financial Inc | 0% | 59 | 0% | 0% | $565 |
| JONES FINANCIAL COMPANIES LLLP | 0% | 29 | 0% | $262 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
2
Headline period
Q2 2026
Rows shown
1-2 of 2